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Abstract
Background: Treatment of cancer patients with anthracycline antibiotic doxorubicin (DOX) may
be complicated by development of acute and chronic congestive heart failure (CHF), malignant
arrhythmias and death. The aim of this study was to test whether an aqueous low molecular weight
(LMW) extract from cod muscle decreases acute mortality in the mouse model of acute CHF
caused by DOX.
Methods: A LMW fraction (<500 Da) of the aqueous phase of cod light muscle (AOX) was used
for treatment of male BALB/c mice (~25 g, n = 70). The animals were divided into four groups,
DOX + AOX (n = 20), DOX + saline (NaCl) (n = 30), NaCl + AOX (n = 10) and NaCl only (n =
10). Echocardiography was performed in the separate subgroups (DOX treated n = 6 and controls
n = 6) to verify the presence and the grade of acute CHF. The cod extract was delivered by
subcutaneously implanted osmotic minipumps over the period of 2 weeks. High-dose injection of
DOX was administered to randomly selected animals. The animals received single intraperitoneal
injection of DOX (25 mg/kg) and were followed over two weeks for mortality.
Results: Mortality rate was 68% lower (p < 0.05) in the mice treated with the extract. The analyses
of cod extract have shown strong antioxidative effect in vitro.
Conclusion: The aqueous LMW cod muscles extract decreases mortality in the mouse model of
DOX induced acute CHF. This effect may be mediated by cardioprotection through antioxidative
mechanisms.
Introduction
The anthracycline antibiotic doxorubicin (DOX) is one of
the most effective antitumor agents against human malig-
nancies such as leukemia, lymphomas and many solid
tumors [1-3]. However, the treatment of cancer patients
with DOX may be complicated by deleterious side effects.
One of the most feared side effects of DOX is a direct dam-
age to the heart which may lead to the development of
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nant arrhythmias and death [4,5]. The acute form of car-
diotoxicity may occur within a week of the treatment and
is not dose-depended, indeed, it may occur after a single
dose of the agent. On the other hand, the incidence of the
chronic CHF at specific cumulative doses of doxorubicin
include 0.4% at 400 mg/m2 of body surface area, 7% at
550 mg/m2, and 18% percent at 700 mg/m2 [3]. Electro-
physiologic abnormalities are frequent and are detected as
ECG changes in 20–30% of the patients in form of non-
specific ST and T wave changes, T wave flattening,
decreased QRS voltage and/or prolongation of the QT
interval. Arrhythmias, including ventricular and
supraventricular tachycardias are seen in 0.5–3% of
patients with overall incidence of 0.7% [2]. Many differ-
ent cardioprotective agents have been tested for preven-
tion of DOX toxicity experimentally and clinically but
with limited success[6]. Considering the essential role of
iron and the doxorubicin-iron complex, iron chelators
have been developed against cardiotoxicity where dexra-
zoxane was found to be the most promising drug[7]. Myo-
cardial damage is a consequence of direct DOX
interference with important intracellular homeostatic
processes primarily mediated by increased intracellular
oxidative stress[8]. Intrinsic antioxidative systems in the
cells are normally able to reduce the damage caused by
oxidative stress. Compared to other organs, however, the
heart has inherently lower potential to protect itself from
the free radicals due to the limited number of anti-oxida-
tive systems in the cardiomyocytes[9]. It is therefore
hypothesized that treatment with antioxidants may play
an important role in preventing myocardial damage. The
mouse model of acute DOX toxicity is a simple and read-
ily available small animal model particularly suitable for
screening studies for different cardioprotective interven-
tions[10,11]. In the recent years, there has been an
increased research interest to develop cardioprotective
and other pharmacological therapies from natural sources
like animals and plants of marine origin. A well known
example of such a promising clinical application in the
field of cardiovascular medicine are the fish-derived long
chain n-3 polyunsaturated fatty acids[12,13]. There is evi-
dence that also aqueous fish-derived substances, such as
taurine, have cardioprotective effects[14]. It has been
speculated that these observations are caused by a radical
scavenging mechanism[15]. We hypothesize that aqueous
fish muscle extract may improve survival in mouse model
of acute heart failure.
Methods
Animals
The Animal Ethics Committee of the University of Göte-
borg approved the animal experiments. Male BALB/c mice
(B&K Universal AB) weighing ~25 g were used in all exper-
iments. Fresh whole cod (Gadus morhua) was obtained
from Leröy Allt i Fisk (Göteborg, Sweden).
Preparation of extract from cod muscle
The cod was manually filleted and the light muscle was
separated from skin and dark muscle. The light muscle
was minced, packed in 200 ml polypropylene centrifuge
bottles (200 g in each) and centrifuged at 15 000*g for 2
h at 4°C. The supernatant (press juice) was filtered
through a filter paper (1010, Munktell's, Swedish Filter
paper, Grycksbo pappersbruk AB, Sweden) and frozen
immediately at -80°C. Using a stirred 400 ml Amicon
ultra filtration cell (Model 52, Amicon Corporation, Dan-
vers, MA, USA), 50 ml of thawed cod muscle press juice
was filtered through a 500 Da ultrafiltration membrane
(Millipore Corporation, Bedford, MA, USA) at 50 psi and
4°C. The first 25 ml of filtrate were collected and the pH
was adjusted to 7.2 with 1 M NaOH. The filtrates were
then immediately frozen at -80°C.
Animal model
To evaluate whether the cod extract may be delivered sub-
cutaneously without provocation of an inflammatory
response, three animals were treated with the extract
delivered by subcutaneously implanted osmotic pumps
(Alzet, Durect Corp., Cupertino, USA, Model NO. 2002).
The animals were followed up for 10 days and were
inspected for signs of skin irritation and possible abscess
formation. No signs of inflammation were found in the
region after 10 days of follow-up.
Transthoracal echocardiography
One day after injection of DOX, echocardiography was
performed in the subgroup of DOX treated mice (n = 6)
and compared to the normal animals (n = 6). The purpose
of this examination was to validate the model of acute
DOX-induced cardiotoxicity i.e. to detect and measure the
extent of cardiac damage. The examination was performed
according to the previously described method[16].
Echocardiographic images were obtained using a com-
mercially available ultrasound system (ATL, Philip Medi-
cal System, Best) equipped with a 15 MHz linear
transducer.
Survival study
A total of 70 mice were divided into the following four
groups: mice treated with DOX and cod muscle extract
(DOX + AOX, n = 20), mice treated with DOX receiving
saline (DOX + NaCl, n = 30), normal mice treated with
cod extract and saline (AOX + NaCl, n = 10) and normal
mice treated only with saline (NaCl, n = 10) (Figure 1).
The average daily doses of cod extract and saline given to
the mice were 12 μL/day. The AOX + DOX and the AOX +
NaCl groups were pre-treated with AOX by means of
osmotic pumps. The DOX + NaCl and NaCl groupsPage 2 of 10
(page number not for citation purposes)
Journal of Experimental & Clinical Cancer Research 2008, 27:81 http://www.jeccr.com/content/27/1/81received 0.9% solution of NaCl in the same manner. After
8 days of pretreatment, the DOX + AOX and the DOX +
NaCl group received a single dose of DOX (25 mg/kg,
Pfizer, Sollentuna, Sweden) by means of intraperitoneal
injection. The AOX + NaCl and NaCl groups were injected
with 0.9% solution of NaCl in the same manner. Mortal-
ity and health conditions were monitored daily for 14
days.
Analysis of ATP, ADP and AMP
The concentrations of myocardial ATP, ADP, and AMP
were determined by high performance liquid chromatog-
raphy (HPLC) from the animals that have survived 2
weeks according to the method previously described[17].
The heart was explanted and immediately frozen in liquid
nitrogen. The samples were maintained in a -134°C until
final analysis. After preparation of the samples, the metab-
olites were separated after polarity in a column (Phenom-
enex® Luna 5 u C18 colonn) and analyzed on standard
HPLC system (Gynkotek, Germering Germany).
Analysis of moisture content, pH and conductivity
The moisture content of the cod extract was measured
using a HA300 Moisture Balance (Precisa balance 310 M,
Zurich, Switzerland) (n = 2). The moisture results were
expressed as percentage of wet weight. A Hamilton double
pour electrode (Hamilton Double Pore, Bonaduz, Swit-
zerland) in conjunction with a pH-meter (Radiometer
analytical PHM210, Villeurbanne Cedex, France) was
used for pH measurements. Conductivity was measured
with a conductivity meter (CDM 210, Meter Lab, Radiom-
eter Analy SAS, Villeurbanne Cedex, France).
Schematically depicted experimental study designFigure 1
Schematically depicted experimental study design. The press-juice consisting of LMW aqueous extract of the codfish was pre-
pared and administered to the randomly selected mice eight days prior to the administration of single high-dose injection of 
doxorubicin. The animals were followed-up during two weeks for survival. ATP = adenosine-tri-phosphate, ADP = adenosine-
diphosphate, AMP = adenosine-monophosphate, AOX = codfish extract, DOX = doxorubicin, NaCl = salinePage 3 of 10
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Total protein measurements of the cod extract were done
according to Lowry et al[18] (n = 2). Protein content was
expressed as mg/mL of sample.
Analysis of total lipids
The method described by Lee et al[19] was used to deter-
mine the total lipids in the cod extract using chloroform
and methanol (1:1) as the extraction solvent (n = 2).
Analysis of ascorbic acid and uric acid
Ascorbic acid and uric acid of the cod extract was analyzed
with HPLC using an electrochemical detector[20], with
modifications according to Gunnarsson et al. [21] (n = 3).
Both ascorbic acid and uric acid results are expressed as
μM.
Analysis of amino acids
Total amino acids, free amino acids and some di-peptides
like carnosine and anserine in the cod extract were ana-
lyzed with HPLC according to Fontaine et al. [22] (n = 2).
Results were expressed as g/kg.
Analysis of the capacity of the cod extract to scavenge 
peroxyl radicals and to prevent ROS formation from 
human monocytes
The antioxidative capacity of the cod extract was analyzed
quantitatively in vitro. These tests were based on the meas-
urement of capacity to scavenge peroxyl radical activity
using the Oxygen Radical Absorbance Capacity (ORAC)
test and to scavenge reactive oxygen species (ROS) pro-
duced by phorbol myristate acetate (PMA) in stimulated
human monocytes. The ORAC test, the method for isolat-
ing monocytes from human blood, and the method for
analyzing whether the cod extract could prevent phorbol
myristate acetate (PMA) initiated ROS formation of the
monocytes is described by Gunnarsson et al[21]. In brief,
the ROS-preventing effect of the cod extract was analyzed
as a relative reduction in the isoluminol-enhanced chemi-
luminescence (CL) signal given by the monocyte-derived
ROS. Thus, the CL-signal given by the monocytes in the
presence of the cod extract was compared with a control
assay where no extract was added.
Statistics
Computer software (StatView 5.0.1) was used to perform
standard statistical procedures. Mortality rate was tested
using a 2 × 2 contingency table. Fisher's PLSD (Protected
Least Significant Difference) test proceeded by one-way
analysis of variance (ANOVA) was applied to detect signif-
icant differences between different treatments for interac-
tions defined in advance. The value p < 0.05 was
considered as statistically significant. All data are pre-
sented as mean ± SEM.
Results
Animals
All animals treated with DOX have shown lower BW (data
not shown), appeared weak and lethargic. At necropsy,
the most prominent gross pathologic change in the mice
treated with DOX was excessive amounts of pericardial,
pleural and peritoneal fluid indicating the presence of sys-
temic as well as local toxic effect. On a gross pathological
cardiac examination the hearts of the DOX treated ani-
mals were enlarged and there were signs of pericarditis
with multiple adhesions of connective tissue formed
between the pericardium and the inner thoracic wall. Fur-
thermore, the epicardial surface was rich in areas of local
fibrosis. These signs were not present in the control ani-
mals. No difference in the BW was found between the
DOX + AOX and the DOX + NaCl groups. The DOX +
AOX mice had less pronounced accumulation of pericar-
dial, pleural and peritoneal fluid compared to the DOX +
NaCl mice.
Analyses of myocardial purine nucleotides
There was no difference between the groups concerning
the amount of myocardial ATP, ADP or AMP (Table 1).
Echocardiography
Echocardiography performed in the subgroup of the
DOX-treated animals has demonstrated the presence of
severely impaired LV function (Table 2). Compared to the
normal controls, the DOX treated mice had lower frac-
tional shortening (FS), cardiac output (CO), stroke vol-
ume (SV) and heart rate (HR) (all p < 0.05). There were
signs of early LV remodeling with increased LV volumes in
systole and diastole (both p < 0.05) in the DOX treated
mice (Figure 2). These findings demonstrate the presence
of severe myocardial damage induced by DOX.
Survival study
In the DOX + AOX group 8/20 (40%) of animals were
alive at 14 days after the injection of DOX compared to
only 4/30 (13%) in the DOX + NaCl (p < 0.05; Figure 3).
There were no deaths in the control groups that did not
receive DOX.
Table 1: Myocardial content of purine nucleotides determined by 
HPLC
ATP μmol/g ADP μmol/g AMP μmol/g
DOX + AOX (n = 8) 16.2 ± 0.6 9.2 ± 0.8 2.7 ± 0.5
DOX + NaCl (n = 4) 18.6 ± 1.3 9.0 ± 0.3 2.5 ± 0.5
AOX + NaCl (n = 10) 16.2 ± 0.5 10.0 ± 0.4 2.8 ± 0.3
NaCl (n = 10) 15.3 ± 0.5 10.0 ± 0.3 3.0 ± 0.2
ATP = adenosine-tri-phosphate, ADP = adenosine-diphosphate, AMP 
= adenosine-monophosphate, AOX = codfish extract, DOX = 
doxorubicin, NaCl = salinePage 4 of 10
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According to Table 3, the dry matter of the cod extract was
very low, reflecting the LMW-character of its composition.
The natural pH of the extract, prior to adjusting it to 7.2
for administration into the mice, was 6.48. The extract
conductivity was 7.83 mS/cm. The extract was totally defi-
cient of lipids, and had very low protein content (0.33
mg/mL). Since the extract was ultrafiltered it only con-
tained small peptides (<500 Da). Two important LMW
muscle antioxidants were measured, ascorbic acid and
uric acid. Their content was 4.3 and 0.34 μM, respectively.
Both total amino acids (Table 4) and free amino acids,
including certain dipeptides (Table 5), were analyzed. As
the detection limit of the total amino acid method was
higher than that for the free amino acid method, much
fewer amino acids are listed in Table 4 than in Table 5.
Among total amino acids, only taurine, glycine, alanine
and β-alanine were above the detection limit (0.5, 0.5, 0.3
and 0.2 g/L, respectively). Regarding free amino acids, the
highest amount (0.55 g/L) was made up by taurine, fol-
lowed by glycine (0.325 g/L), alanine (0.295 g/L), β-
alanine (0.175 g/L), methylhistidine (0.095 g/L) and
anserine (0.9 g/L); all above or close to 0.1 g/kg. A few
minor amino acids were also detected like threonine,
glutamic acid, proline, valine, methionine, and leucine.
Antioxidant testing of the cod extract using ORAC
According to Table 3, the ORAC-value of the cod extract
was 1.17 mmol trolox equivalents/L sample. In Figure 4,
it is shown that the cod extract, at a 100-fold dilution,
reduced the maximum CL-signal given by monocytes
stimulated with 10 nM of PMA by about 50%.
Discussion
The main results of the study could be summarized as fol-
lows: The LMW cod muscle aqueous extract decreased the
mortality rate in mice following DOX-induced acute CHF.
Table 2: Echocardiography
LVd (mm) LVs (mm) FS (%) CO (ml/min) HR (beats/min)
DOX (n = 6) 4.5 ± 0.2* 3.2 ± 0.2* 28 ± 2* 2.3 ± 1.4* 322 ± 21*
Control (n = 6) 3.7 ± 0.04 2.1 ± 0.07 43 ± 2 14 ± 1.6 406 ± 22
* p < 0.05 v. control
LVd = left ventricular diameter in diastole, LVs = left ventricular diameter in systole, FS = fractional shortening, CO = cardiac output, HR = heart 
rate, DOX = doxorubicin
M-mode tracings of left ventricle (LV) from the mouse treated with doxorubicin (DOX) and the control mouse one day after DOX administrationFigure 2
M-mode tracings of left ventricle (LV) from the mouse treated with doxorubicin (DOX) and the control mouse one day after 
DOX administration. LV dilatation and decreased systolic function are evident in the DOX treated mouse. LVd = left ventricu-
lar diameter in diastole, LVs = left ventricular diameter in systolePage 5 of 10
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scavenging effects in vitro.
To the best of our knowledge, this is the first study to dem-
onstrate the beneficial effect of an aqueous fish extract on
survival rate in an in vivo animal model of acute heart fail-
ure. Cardioprotection has been in the research focus for
many years. Different pharmacological and non-pharma-
cological strategies have been proposed to decrease myo-
cardial damage e.g. during ischemia-reperfusion injury
and cardiotoxicity. However, only few experimental inter-
ventions have been translated into a clinical practice and
with a limited success. Several studies have shown benefi-
cial cardiovascular effects of fish and fish derived sub-
stances. By far the best known are the long chain n-3
polyunsaturated fatty acids[12,13]. These fatty acids may
enter the cellular membrane and alter membrane func-
tions resulting in, e.g., antiarrhythmic effects[12]. Recent
evidence indicates that dietary supplementation with fish
oil preserves normal vasomotion of atherosclerotic coro-
Effect of the codfish extract on acute mortality rate in the mice with doxorubicin induced acute heart failureFigure 3
Effect of the codfish extract on acute mortality rate in the mice with doxorubicin induced acute heart failure. The treatment 
decreased the mortality rate by 50% compared to the control group. * p < 0.05 v. NaCl + DOX
Table 3: Compositional data and ORAC data of the LMW (< 500 Da) fraction of cod press juice.
Measurements Cod extract (<500 Da)
Dry Matter % (n = 2) 1.94
Native pH (n = 2) 6.48
Conductivity (mS/cm) (n = 2) 7.83
Total lipids % (n = 2) Not detected
Total protein (mg/mL) (n = 2) 0.33
Ascorbic acid (μM) (n = 3) 4.30 ± 0.54
Uric acid (μM) (n = 3) 0.34 ± 0.004
ORAC (mmol Trolox equivalents/l sample) (n = 8) 1.17 ± 0.06Page 6 of 10
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ischemia and reperfusion in animal models[23,24]. Much
less is known whether aqueous components of fish, e.g.
proteins, peptides, amino acids and other organic acids
may protect the heart. On a wet weight basis, the aqueous
phase usually contribute to 95–99.5% of the total edible
parts of seafoods. Indeed, the results of the present study
provide the evidence that also aqueous fish-derived com-
pounds may play an important role in cardioprotection.
The mouse model of DOX induced acute heart failure is
suitable for screening studies and is well characterized in
the literature[25]. We have verified the presence of acute
CHF in the animals treated with DOX demonstrating that
already one day after the exposure to the high-dose DOX,
the indices of LV function were severely impaired with
development of early pathologic LV remodeling (Figure
2). It is therefore not surprising that the mortality rate
after high-dose DOX reached ~90% in the untreated ani-
mals. Although several organ systems sustain damage in
this model, the central role in the progression of the mul-
tiorgan failure is the failing heart. Acute myocardial injury
is a result of pathophysiological abnormalities that are
caused by direct toxic intracellular actions of DOX and
include inhibition of nucleic acid and protein synthesis,
release of vasoactive amines, alteration in adrenergic func-
tion, mitochondrial abnormalities, lysosomal changes,
modification of sarcolemma Ca2+ transport, attenuation
of adenyl-cyclase, Na+-K+-ATPase, and Ca2++-ATPase activ-
ities, imbalance in myocardial electrolytes. However,
most of the studies support the view that oxidative stress
holds the central role in the development of these
derangements (see ref. [8] for review). Our study does not
provide the exact explanation for the possible mecha-
nisms behind the improved survival rate. Given the fact
that cardiotoxicity with acute heart failure is the primary
cause of death in this model, we speculate that the treat-
ment was primarily cardioprotective. At the cellular level,
this cardioprotection may have been mediated by antiox-
idative effects and/or by other mechanisms. Others have
shown that increasing antioxidative capacity of the heart
muscle suppresses cardiotoxicity of DOX[26]. The aque-
ous LMW-cod extract used in this study was reported to
possess strong antioxidative effects[27]. However, it has
not been previously evaluated whether this extract exerts
antioxidative properties under physiological conditions.
The results shown in Figure 3, 4 and Table 3 provide evi-
dence for such an effect. The data from human monocytes
in Figure 4 indicate that the capacity of the cod extract to
prevent ROS-formation is ~50% at a 100-fold dilution! To
evaluate the contribution of some individual compounds
of the cod extract to its total antioxidative capacity (ORAC
Effect of the LMW cod extract (1/100 dilution) on the chemiluminescence from monocytes induced by 10 nM of PMAFigure 4
Effect of the LMW cod extract (1/100 dilution) on the chemiluminescence from monocytes induced by 10 nM of PMA. Control 
contains buffer instead of cod extract.Page 7 of 10
(page number not for citation purposes)
Journal of Experimental & Clinical Cancer Research 2008, 27:81 http://www.jeccr.com/content/27/1/81value) it was compared to some previously reported
ORAC values for solutions of pure ascorbic acid and uric
acid at the equimolar levels to those measured in the cod
extract[28]. These substances had ORAC values three
orders of magnitude lower than the cod extract, indicating
that other compounds in the extract appear to be involved
in its radical scavenging effect and/or that antioxidative
substances require other LMW-compounds present at the
same time for regeneration purposes. Which are the most
likely candidates in the extract that have provided organ
protection and survival benefit in this study? The LMW-
compounds of fish muscle that has been ascribed antiox-
idative properties include ascorbic acid, uric acid, glutath-
ione, various polyamines, histidine containing dipeptides
(anserine, carnosine) and free amino acids (taurine, histi-
dine). Based on the quantitative analyses (Table 3, 4, 5)
we speculate that taurine and anserine might have been
responsible for the most part of the protection. Taurine is
generally found in high levels in seafood[29]. It is
involved in radical scavenging, membrane regulation,
osmoregulation and regulation of calcium homeosta-
sis[30]. In animal models and human trials in the settings
of CHF, taurine was found to have beneficial effects on
cardiac function and morphology[31,32]. Similarly,
anserine has shown antioxidative effects at physiological
levels in different in vitro systems[33]. We did not find
any differences between the groups in regard to myocar-
dial contents of ATP, ADP or AMP. Unexpectedly the DOX
treated groups did not show lower ATP levels. One possi-
ble explanation for this result may be the selection bias
since this analysis was performed only on biopsies from
the surviving mice.
There are some limitations that deserve to be mentioned.
We have not compared the efficacy of the cod muscle
extract to other known cardioprotective agents such as
dexrazoxane. We have not demonstrated specific cardio-
protective effects of the extract in terms of cardiac function
(echocardiography) or tissue structure (pathohistology).
Furthermore, our study does not provide the answer to
whether the survival benefit is mediated by few com-
Table 4: Composition of total amino acids in Cod LMW-PJ (<500 
Da).
Average g/L sample Cod LMW-PJ (<500 Da)
Taurine 0.5 ± 0
Cysteine <0.1
Methionine <0.1
Aspartic acid <0.1
Threonine <0.1
Serine <0.1
Glutamic acid <0.1
Proline <0.1
Glycine 0.5 ± 0
Alanine 0.3 ± 0
β-Alanine 0.2 ± 0
Valine <0.1
Isoleucine <0.1
Leucine <0.1
Tyrosine <0.1
Phenyl alanine <0.1
Histidine <0.1
Ornithine <0.1
Lysine <0.1
Arginine <0.1
Hydroxyproline <0.1
Sum 1.5
Table 5: Composition of free amino acids and certain dipeptides 
in Cod LMW-aqueous extract (<500 Da).
g/L Cod extract (<500 Da)
Phosphoserine <0.02
Taurine 0.55 ± 0
Phosphoethanolamine <0.02
Urea 0.07 ± 0.01
Aspartic acid <0.02
Threonine 0.04 ± 0
Serine 0.03 ± 0
Aspargine <0.02
Glutamic acid 0.04 ± 0
Sarcosine <0.02
α-Aminoadipitic acid <0.02
Proline 0.035 ± 0.005
Glycine 0.325 ± 0.005
Alanine 0.295 ± 0.005
Citrulline <0.02
α-Amino-n-butyric acid <0.02
Valine 0.04 ± 0
Cysteine <0.02
Methonine 0.02 ± 0
Cystathionine <0.02
Isoleucine <0.02
Leucine 0.04 ± 0
Tyrosine <0.02
β-Alanine 0.175 ± 0.015
Phenyl alanine <0.02
β-Aminoisobutyric acid <0.02
L-Homocystine <0.02
γ-Amino-n-butyric acid <0.02
Ethanolamine <0.02
Ammonia 0.08 ± 0
γ-Hydroxilysine <0.02
Ornithine <0.02
Lysine <0.02
1-Methylhistidine 0.095 ± 0.005
Histidine <0.02
3-Metylhistidine <0.02
Anserine 0.09 ± 0
Carnosine <0.02
Arginine <0.02
Hydroxiproline <0.02
Glutamine <0.02Page 8 of 10
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multiple compounds optimally mixed in this preparation.
In conclusion, the aqueous LMW cod muscles extract
decreases mortality in the mouse model of DOX induced
acute CHF. This effect may be mediated by cardioprotec-
tion through antioxidative mechanisms.
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